Raymond James on BridgeBio Pharma (BBIO): 'We expect the topline nominal win for HELIOS-B will send BBIO shares downward'
Raymond James analyst Danielle Brill reiterated an Outperform rating and $46.00 price target on BridgeBio Pharma (NASDAQ: BBIO).The analyst comments ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)